Dongwha Pharm announced on July 6 that ECCLOCK Gel, the first prescription medication for primary axillary hyperhidrosis among topical agents in Korea, has been adopted by 24 major hospitals within five months of its launch.


Product image of Dong Wha Pharm Eclac Gel. Dong Wha Pharm

Product image of Dong Wha Pharm Eclac Gel. Dong Wha Pharm

View original image

ECCLOCK Gel is a topical gel formulation containing sofpironium bromide, which reduces excessive sweating by blocking the signal for sweat secretion at the sweat glands.


In the human body, acetylcholine released from the sympathetic nerve endings stimulates the muscarinic receptor (M3) on sweat glands, transmitting the signal for sweat secretion. The main ingredient in ECCLOCK Gel, sofpironium bromide, competitively binds to the muscarinic receptors, which are the key mediators in sweat secretion signaling, thereby blocking the action of acetylcholine and suppressing the signal transmitted to the sweat glands.


ECCLOCK Gel allows effective management of hyperhidrosis with just one daily application to the affected area, providing a new treatment option for axillary hyperhidrosis patients who previously had limited treatment choices such as botulinum toxin injections or sympathectomy.


Cases of compensatory sweating, where sweating decreases at the treated area but increases in other areas, have been rarely reported in clinical trials and post-marketing surveillance (PMS) conducted on Japanese patients. In a post-marketing surveillance study conducted in Japan on approximately 25,800 people, only two cases of compensatory sweating were reported as adverse events.



In addition, the product features a twist-type container, which improves ease of use by allowing direct application to the affected area without the need to touch the medication by hand.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing